logo
Conspiracy Theorists Are Creating Special AIs to Agree With Their Bizarre Delusions

Conspiracy Theorists Are Creating Special AIs to Agree With Their Bizarre Delusions

Yahoo23-06-2025
Conspiracy theorists are using AI chatbots not only to convince themselves of their harebrained beliefs, but to recruit other users on social media.
As independent Australian news site Crikey reports, conspiracy theorists are having extensive conversations with AI chatbots to "prove" their beliefs. Then, they post the transcripts and videos on social media as "proof" to others.
According to the outlet's fascinating reporting, there are already several bots specifically trained on harebrained conspiracy theories, including a custom bot designed to convince parents not to vaccinate their children.
The news highlights a troubling trend, with countless ChatGPT users developing bizarre delusions and even spiraling into severe mental health crises, as we reported last week. Experts have warned that AI chatbots are designed to be incredibly sycophantic, predisposing them to agreeing with users even when doing so is clearly harmful.
Much like delusions of spiritual awakenings, messianic complexes, and boundless paranoia, conspiracy theorists are finding the perfect conversational partner in tools like ChatGPT.
Since they were trained on the open web — an enormous data set that includes unfounded conspiracy theories, like the belief that vaccines cause autism — they can easily be coaxed into furthering these theories.
As Crikey reports, one chatbot called Neo-LLM was trained by a Texan anti-vaxxer using over 100,000 dubious articles from the far-right conspiracy theory news website Natural News.
It's unclear how many users have downloaded the chatbot, but promotional videos have garnered tens of thousands of views.
In short, it's an alarming trend that shows the dangers of powerful AI chatbot tech falling into the wrong hands. In particular, people suffering from mental health issues can be convinced they're talking to a real authority, rather than a parroting language model that continuously calculates the probability of the next word.
That kind of delusion can have devastating consequences. As the New York Times reported last week, a 35-year-old man — who had previously been diagnosed with bipolar disorder and schizophrenia before becoming obsessed with ChatGPT — was shot and killed by police after he charged at them with a knife following a mental health crisis centering on the bot.
Since AI chatbots have become incredibly effective at generating convincing-sounding answers, their ill use could have real-life implications. Researchers have shown that AI chatbots can easily be weaponized and taught how to spew an endless firehose of disinformation.
With the Trump administration actively rolling back AI regulations and key politicians furthering anti-vaccine conspiracy theories themselves, the future looks bleak. Even tech companies have historically failed to implement effective guardrails to stop chatbots from hallucinating.
However, some experts have pondered if the tech could be used for good as well. Last year, researchers at MIT found that chatbots can also be used to reduce the belief in conspiracy theories, a glimmer of hope as the internet becomes increasingly polluted with deranged, AI-generated claims.
More on AI delusions: People Are Becoming Obsessed with ChatGPT and Spiraling Into Severe Delusions
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New weekly injection for Parkinson's could replace daily pill for millions, study suggests
New weekly injection for Parkinson's could replace daily pill for millions, study suggests

Fox News

timean hour ago

  • Fox News

New weekly injection for Parkinson's could replace daily pill for millions, study suggests

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, potentially replacing the need for daily pills. Scientists from the University of South Australia (UniSA) developed a long-acting injectable formulation that provides two key Parkinson's medications for an entire week. There is currently no cure for Parkinson's, which is the second-most common neurological disorder, affecting more than one million Americans, according to the Parkinson's Foundation. To manage symptoms like tremors, rigidity and slow movement, patients typically take daily oral medications, such as levodopa and carbidopa, according to the university's press release. This method can be especially difficult for individuals who have trouble swallowing or are otherwise unable to take the pills consistently, leading to irregular medication levels, increased side effects and reduced effectiveness. Levodopa is the "gold-standard therapy for Parkinson's," according to lead researcher Professor Sanjay Garg at UniSA, but its short lifespan means it must be taken several times a day. The researchers tested an injectable gel implant that combines an FDA-approved biodegradable substance with a pH-sensitive substance to achieve a controlled and sustained drug release. The gel is injected through a single shot under the skin or into the muscle tissue, which means there's no need for a surgical implant and discomfort is minimal, they noted. The team found that the gel gradually released the key Parkinson's medications (90% of the levodopa drug and 81% of the carbidopa) over the course of one week. The findings were published in the journal Drug Delivery and Translational Research. "Reducing the frequency of dosing from multiple times a day to a weekly injection is a major step forward in Parkinson's therapy," Garg said in the release. "We're not just improving how the drug is delivered; we're improving patients' lives." Extensive lab tests confirmed the system's effectiveness and safety. "We're not just improving how the drug is delivered; we're improving patients' lives." The implant degraded by over 80% within a week and showed no significant toxicity in cell viability tests. "The implications of this research are profound," Garg added. Deepa Nakmode, a PhD student at the University of South Australia, noted that this method is designed to release both levodopa and carbidopa steadily over one week, maintaining consistent plasma levels and reducing the risks associated with fluctuating drug concentrations. "After years of focused research, it's incredibly rewarding to see our innovation in long-acting injectables for Parkinson's disease reach this stage," he said in the release. The team's invention has now been filed for an Australian patent, Nakmode added. The technology could also be adapted for other chronic conditions, such as cancer, diabetes, neurodegenerative disorders, chronic pain and infections that require long-term drug delivery, according to Garg. The system can be tuned to release drugs over a period ranging from a few days to several weeks, depending on therapeutic needs. For more Health articles, visit Scientists hope to start clinical trials in the near future and are exploring opportunities to make the gel commercially available.

FDA Issues Highest Risk Warning for Vegetable Recall
FDA Issues Highest Risk Warning for Vegetable Recall

Newsweek

timean hour ago

  • Newsweek

FDA Issues Highest Risk Warning for Vegetable Recall

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recall of a range of vegetable products due to potential contamination with Listeria monocytogenes has been issued the highest risk classification by the U.S. Food and Drug Administration (FDA). And Go Concepts LLC, doing business as Salad and Go, a Texas-based company, announced a voluntary recall for the products on May 27. The FDA subsequently issued a Class 1 risk classification for the recall on July 11. Newsweek contacted And Go Concepts LLC for comment by email outside of regular working hours. Salad and Go announced a voluntary recall for a range of vegetable products due to potential listeria contamination on May 27. Salad and Go announced a voluntary recall for a range of vegetable products due to potential listeria contamination on May 27. Edwin Remsberg/VWPics/AP Why It Matters A Class I risk classification represents "a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death," according to the FDA. Listeria infection, or listeriosis, may lead to a range of symptoms in infected individuals. For those experiencing less severe infections, symptoms may include fever, muscle aches, nausea, vomiting and diarrhea, which often last between one and three days, the FDA said. For more severe and potentially life-threatening infections, symptoms may include headaches, stiff neck, confusion, loss of balance and convulsions. Severe infections are particularly dangerous for young children, frail or elderly people, and those with weakened immune systems. It can also lead to miscarriages and stillbirths in pregnant women. What To Know The products affected by the recall include the following: Red cabbage, shredded - 1 case - codes: 2514111 / 2514111B Onion, red diced - 8 cases (80 bags) - codes: 2514111 / 2514111B / 2514211 / 2514211B / 2514311 Cucumber, sliced - 8 cases (80 bags) - codes: 2514111 / 2514311 Pepper, red bell chopped - 31 cases (220 bags) - codes: 2514111 / 2514111B / 2514311 Carrot, shredded - 16 cases (195 bags) - codes: 2514111 / 2514311 Tomato, grape - 141 cases (565 bags) - codes: 2514111 / 2514111B / 2514211 Potato, cooked breakfast - codes: 2514111 / 2514111B / 2514311 Brussels sprouts, roasted - 71 cases - codes: 2514111 / 2514111B / 2514311 The products were distributed in Arizona and Nevada. What People Are Saying Mary O'Riordan, a professor of microbiology and immunology at the University of Michigan Medical School, told Newsweek previously: "Listeria has an unusual capacity to grow at refrigerated temperatures. Although the bacterium can contaminate many types of food, cheeses or deli meats that are kept in cold storage for long periods in stores or at home are a place where listeria can keep growing. "Early symptoms of listeria infection look similar to other common foodborne infections, including fever, diarrhea and vomiting, so it's often not diagnosed right away. Unfortunately, sometimes listeria can spread into the brain and cause more serious illness, like meningitis. In those cases, if people experience headache, stiff neck or confusion, they should seek urgent medical attention." Haley F. Oliver, a professor of food science at Purdue University, told Newsweek previously: "Listeria monocytogenes is a common microorganism that can be found in the natural environment, for example in soil. There are many factors that determine if someone gets listeriosis—a listeria infection. In most instances, an immunocompromised person—so young, old, pregnant or otherwise immunocompromised—must eat contaminated food. The number of bacteria resulting in infection and the amount of time before illness varies considerably. Symptoms vary among people but can include fever, flu-like symptoms, headache, stiff neck, confusion and loss of balance." The FDA says on its website: "Pregnant women and their unborn or newborn baby, adults over the age of 65, and those with weakened immune systems, are all considered to be high-risk groups that are susceptible to the serious and adverse effects of listeriosis." What Happens Next The recall is listed as completed, according to the FDA.

Rpharmy CEO Laura Paxton Recognized in Becker's Hospital Review's ‘Women in Health IT to Know' List
Rpharmy CEO Laura Paxton Recognized in Becker's Hospital Review's ‘Women in Health IT to Know' List

Yahoo

time2 hours ago

  • Yahoo

Rpharmy CEO Laura Paxton Recognized in Becker's Hospital Review's ‘Women in Health IT to Know' List

Annual List Celebrates Innovative Women in Health IT Who Are Committed to Improving Healthcare Through Technology Laura Paxton, Founder and CEO of Rpharmy AUSTIN, Texas, July 15, 2025 (GLOBE NEWSWIRE) -- Rpharmy, a leading provider of medical formulary management and hazardous drug safety information software solutions, today announced that its founder and CEO, Laura Paxton, is one of the Becker's Hospital Review 2025 'Women in Health IT to Know.' The complete list features individual profiles of all women on the list and can be read here. Becker's Hospital Review said the leaders celebrated on this list are using technology to drive meaningful change by streamlining administrative processes, enhancing care delivery, standardizing workflows, and elevating overall system efficiency. Becker's Healthcare is proud to honor these trailblazing women in health IT for their unwavering commitment to improving healthcare. Their leadership and innovation are essential to the continued success of their organizations and the industry as a whole. 'It's a tremendous honor to be included among such an extraordinary group of women, all of whom share a deep commitment to advancing healthcare through technology,' said Paxton. 'Over the past 30 years in this industry, I've witnessed a remarkable evolution, not just in the innovations that are transforming patient care and worker safety, but in the growing influence of women in healthcare IT. It's truly gratifying to see the intelligence, leadership, and ingenuity that women bring to these essential roles being acknowledged by Becker's Healthcare.' As CEO of Rpharmy, Paxton leads the company's mission to enhance patient and healthcare worker safety through innovative, user-centered technology. What makes Laura Paxton stand out in healthcare IT isn't just her technology—it's her relentless focus on solving problems that others overlook. Paxton has pioneered tools that protect both patients and healthcare workers while building a culture of safety, equity, and practical innovation. Under her direction, Rpharmy developed Formweb, a cloud-based formulary and safety platform that consolidates high-alert medications, REMS data, Black Box warnings, and facility-specific protocols into a single source of truth. More than just a formulary, it serves as a communication hub for safer medication practices across health systems. Paxton also led the creation of Rhazdrugs, the first comprehensive software dedicated to hazardous drug safety and USP <800> compliance. This solution was developed through constant engagement with nurses, pharmacists, and health system leaders who voiced concerns about the lack of clear, accessible safety guidance. The Becker's Hospital Review editorial team accepted nominations for this list and curated it to highlight the great work of women in health IT. To learn more about nominations, visit About RpharmyFor more than 30 years, Rpharmy has been solving problems related to medication safety and patient care. We develop and provide technology focused on medical formulary, hazardous drug handling, and HFAP, NIOSH, and Joint Commission compliance. Our primary desire is to keep all patients and healthcare workers safe through easy access to critical medication safety information. For more information, visit Media Contact:Carrie Ward, PR for Rpharmy, 832-407-5347, carrie@ A photo accompanying this announcement is available at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store